SynthesisRevista do Instituto de Medicina Tropical de Sao Paulo2020
Prevalence of comorbidities in patients and mortality cases affected by SARS-CoV2: a systematic review and meta-analysis.
Synthesis in Revista do Instituto de Medicina Tropical de Sao Paulo, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05897528 (Impaired Insulin Regulation Determining Severity of Severe Acute Respiratory Syndrome COVID-19 Infection Confounded by Ethnicity), which is not on this map. Cited by 60 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Impaired Insulin Regulation Determining Severity of Severe Acute Respiratory Syndrome COVID-19 Infection Confounded by Ethnicity
Who cites it
60 citing papers in PubMed, 6 syntheses or guidelines pooled it.
- The impact of cancer on the severity of disease in patients affected with COVID-19: an umbrella review and meta-meta-analysis of systematic reviews and meta-analyses involving 1,064,476 participants.Clinical and experimental medicine · 2023Pooled it
- Effects of SARS-CoV-2 infections in patients with cancer on mortality, ICU admission and incidence: a systematic review with meta-analysis involving 709,908 participants and 31,732 cancer patients.Journal of cancer research and clinical oncology · 2023Pooled it
- Prevalence of hypertension and associated risks in hospitalized patients with COVID-19: a meta-analysis of meta-analyses with 1468 studies and 1,281,510 patients.Systematic reviews · 2022Pooled it
- Risks of and From SARS-CoV-2 Infection and COVID-19 in People With Diabetes: A Systematic Review of Reviews.Diabetes care · 2021Pooled it
- Effects of cancer on patients with COVID-19: a systematic review and meta-analysis of 63,019 participants.Cancer biology & medicine · 2021Pooled it
- Is there any potential management against COVID-19? A systematic review and meta-analysis.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2020Pooled it
- Assessing Adherence to Preventive Behaviors Among Patients with Mental Illness in the Context of the COVID-19 Pandemic: A Scoping Review.International journal of environmental research and public health · 2026Article
- Acute and chronic kidney injury following COVID-19 infection and vaccination: a narrative review.European journal of translational myology · 2026Article
- Altitude and case fatality rate from COVID-19 during the pandemic in Peru, 2020-2022.Revista peruana de medicina experimental y salud publica · 2026Article
- Impact of comorbidities on management and outcomes of patients weaning from invasive mechanical ventilation: insights from the WEAN SAFE study.Critical care (London, England) · 2025Article
- COVID-19 case fatality ratio and survival among hospitalized adults in Goiás, 2020: a cohort study.Epidemiologia e servicos de saude : revista do Sistema Unico de Saude do Brasil · 2025Article
- Association of COVID-19 With Emergence of Comorbidities: A Hospital-Based Cohort Study.Cureus · 2024Article
- Statin therapy impact on Long-Term outcomes in acute heart Failure: Retrospective analysis of hospitalized patients.International journal of cardiology. Heart & vasculature · 2024Article
- The impact of comorbidities and economic inequality on COVID-19 mortality in Mexico: a machine learning approach.Frontiers in big data · 2024Article
- The impact of impaired insulin regulation on severity of SARS-CoV-2 infection: a 2-year retrospective single-center analysis.Annals of medicine and surgery (2012) · 2023Article
- Diabetes and deaths of COVID-19 patients: Systematic review of meta-analyses.Health sciences review (Oxford, England) · 2023Review
- Psoriasis comorbidity management in the COVID era: a pressing challenge.Frontiers in microbiology · 2023Review
- Article
- Development and validation of a predictive scoring system for in-hospital mortality in COVID-19 Egyptian patients: a retrospective study.Scientific reports · 2022Article
- Machine learning and comorbidity network analysis for hospitalized patients with COVID-19 in a city in Southern Brazil.Smart health (Amsterdam, Netherlands) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The new coronavirus, COVID-19 was declared a pandemic by the World Health Organization on March 11, 2020. Risk factors associated with this disease are age, sex, and the presence of comorbidities, the most common being hypertension, diabetes, and heart disease. The aim of this meta-analysis was to calculate the prevalence and geographical distribution of comorbidities in all patients admitted to intensive care units (ICUs), and the mortality rate of COVID-19. We selected studies based upon epidemiological and clinical descriptions of the patients and mortality from the disease to determine the pooled prevalence of comorbidities in all patients and in mortality cases due to COVID-19. The pooled prevalence was estimated using the random effects model, and odds ratios were used to measure the probability of death for a patient with a comorbidity. The total prevalence of comorbidities in patients with COVID-19 was 42% (95% CI: 25-60), 61% (95% CI: 42-80) in those admitted to the ICU, and 77% (95% CI: 68-86) among death cases; males were the most affected. Hypertension was the most prevalent comorbidity in all three groups studied, accounting for 32%, 26%, and 35%, respectively. The odds ratio of death for a patient with a comorbidity compared to one with no comorbidity was 2.4 (P < 0.0001). The higher the prevalence of comorbidities the higher the odds that the COVID-19 patient will need intensive care or will die, especially if the pre-existing disease is hypertension, heart disease, or diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.